Polar Capital Holdings’s Taysha Gene Therapies TSHA Stock Holding History

Polar Capital Holdings’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.8M	Sell	5,117,133 -537,207	-10%	-$3.18M	0.08%	146
2026 Q1	$25.3M	Sell	5,654,340 -2,277,063	-29%	-$10.6M	0.09%	130
2025 Q4	$43.6M	Buy	7,931,403 +2,637,524	+50%	+$12.8M	0.17%	107
2025 Q3	$17.3M	Buy	5,293,879 +293,879	+6%	+$832K	0.08%	165
2025 Q2	$11.6M	Buy	5,000,000 +2,000,000	+67%	+$4.35M	0.06%	178
2025 Q1	$4.17M	Hold	3,000,000	–	–	0.03%	238
2024 Q4	$5.19M	Sell	3,000,000 -25,000	-0.8%	-$51.9K	0.03%	247
2024 Q3	$6.08M	Hold	3,025,000	–	–	0.03%	233
2024 Q2	$6.78M	Buy	3,025,000 +506,091	+20%	+$1.47M	0.04%	217
2024 Q1	$7.23M	Hold	2,518,909	–	–	0.04%	221
2023 Q4	$4.46M	Sell	2,518,909 -11,091	-0.4%	-$22.1K	0.03%	237
2023 Q3	$7.99M	Buy	+2,530,000	New	+$4.73M	0.06%	202

Other funds holding TSHA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital Holdings's TSHA Position: Q2 2026 in Review

Polar Capital Holdings reduced its Taysha Gene Therapies (TSHA) stake by 9.5% in Q2 2026, selling an estimated $3.18M and leaving 5,117,133 shares worth $34.8M. The position accounts for 0.08% of the portfolio, ranked #146.

Polar Capital Holdings first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. The position peaked at $43.6M in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Polar Capital Holdings held 5,117,133 shares of Taysha Gene Therapies worth $34.8M as of Q2 2026.
Polar Capital Holdings sold 537,207 Taysha Gene Therapies shares in Q2 2026, an estimated $3.18M.
Taysha Gene Therapies made up 0.08% of Polar Capital Holdings's portfolio in Q2 2026, its #146 holding.
Polar Capital Holdings first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
Polar Capital Holdings's Taysha Gene Therapies position peaked at $43.6M in Q4 2025.
209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.